Beneficial effects of Cuscuta chinensis extract on glucocorticoid-induced osteoporosis through modulation of RANKL/OPG signals

Abstract

Cuscuta chinensis Lam. (Convolvulaceae) is an important herbal medicine widely used to improve sexual function, treat osteoporosis, and prevent aging, and has been reported to exhibit anti-osteoporotic effects in vitro. However, the activity of Cuscuta chinensis Lam. on glucocorticoid-induced osteoporosis still remains unclear. The present study aimed to assess the protective effect and the underlying mechanism of action of Cuscuta chinensis extract (CCE) against glucocorticoidinduced osteoporosis in vivo. Sprague-Dawley rats were randomly divided into four groups as follows: control group, osteoporosis group, and 2 CCE-treated osteoporosis groups (100 mg Á kg-1 Á day-1). Blood samples and femur bones were collected for immunohistochemistry, biochemical, mRNA expression, and western blot analysis. HPLC analysis revealed that chlorogenic acid, quercetin, and hyperin were the major constituents of CCE. The results indicated that CCE increased bone length, bone weight, and bone mineral density and suppressed dexamethasone (DEX)-induced reduction in body weight. In addition, TRAP staining indicated that CCE reduced osteoclasts in DEX-induced osteoporosis rats. Mechanistically, CCE treatment alleviated the increase of bone resorption markers and the decline of osteogenic markers, which might be partially mediated by regulation of RANKL/OPG and RunX2 pathways. These results suggest that CCE showed promising effects in the protection against glucocorticoid-induced osteoporosis through protecting osteoblasts and suppressing osteoclastogenesis.

Bovine Milk Extracellular Vesicles Are Osteoprotective by Increasing Osteocyte Numbers and Targeting RANKL/OPG System in Experimental Models of Bone Loss

“…Our findings indicate that mEVs positively act on the RANKL/OPG system by decreasing their ratio systemically and locally. These data corroborate with other studies, in which a decrease in this ratio is associated with reduced osteoclastogenesis after treatment with plant and root extracts in models of bone loss, such as ovariectomy (Sun et al, 2019;Zhu et al, 2020) or glucocorticoid (Mo et al, 2019). An amelioration in bone structure with the treatment of mEVs was shown by improving the bone stiffness despite some slight effect in the femur microarchitecture in OVX mice.…”

Chondroitin Sulfate Alleviates Diabetic Osteoporosis and Repairs Bone Microstructure via Anti-Oxidation, Anti-Inflammation, and Regulating Bone Metabolism

“…RANKL activates osteoclast differentiation, thus promoting bone resorption by competing with OPG to bind to receptor RANK. Overexpression of RANKL can lead to excessive activation of osteoclasts, which can lead to osteoporosis ( 41 ). OPG was also a member of the TNF superfamily.…”

Aucubin slows the development of osteoporosis by inhibiting osteoclast differentiation via the nuclear factor erythroid 2-related factor 2-mediated antioxidation pathway

“… 2018 ; Mo et al. 2019 ). COL I stimulates the transcription of osteoblast-formation genes and is the main component of the skeletal matrix, and CTSK degrades COL I (Qiu et al.…”